Douglas Berger Psychiatrist Tokyo – About Dr. Douglas Berger

Douglas-Berger-Tokyo-psychiatrist
Douglas Berger psychiatrist Tokyo

Dr. Douglas Berger, M.D., Ph.D., Meguro Counseling Center Director

Douglas Berger, M.D., Ph.D., a fully bilingual American board certified psychiatrist, is the Director of the Tokyo Meguro Counseling Center. Dr. Doug Berger is a graduate of New York Medical College where he completed a 4-year residency program in psychiatry. He then finished a fellowship in Psychosomatic Medicine at the Albert Einstein College of Medicine. Now based in Tokyo, he had served on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry and licensed practicing U.S. physician. Dr. Berger’s Japanese qualifications include a Ph.D. from the University of Tokyo School of Medicine received for psychiatric research done while at the Tokyo University Department of Psychosomatic Medicine.

Dr. Berger came to Japan as a medical exchange student and psychiatric researcher at the Tokai University School of Medicine on a research fellowship from the Matsumae International Foundation. He later returned to Japan to do further psychiatric research at the Tokyo University Department of Psychosomatic Medicine and the Tokyo Institute of Psychiatry. Dr. Berger speaks native-level Japanese and regularly conducts psychotherapy for mixed-cultural couples as well as the local Japanese community. This page lists Dr. Berger’s research activity, and this page is an archive of community education articles for the Tokyo Families Magazine written by Dr. Berger. See what we write about on Twitter: Dr. Berger’s Twitter Page Meguro Counseling Center Twitter Page.

Dr. Berger also works extensively with children as Director of the Tokyo Child & Adolescent Counseling Service. Dr. Berger is a legal permanent resident of Japan.

Credential Verifications

Dr. Berger’s medical degree is from the United States, he is well-versed in the use of psychiatric medication and can guide the use of psychiatric medications integrated with psychotherapy through the physicians affiliated with his counseling practice (he does not directly practice medical care in Japan). Further information on Dr. Berger can be seen on his personal home page.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine.

Click here to see a full list of articles.

For more information on Dr. Doug Berger, read some of the articles here.

To contact Douglas Berger psychiatrist Tokyo please click here

Douglas Berger Tokyo psychiatrist: Brain changes in Mindfulness Based therapy https://t.co/zpuzl9UBif

Douglas Berger Tokyo psychiatrist: Many therapy studies call themselves, “single-blind” https://t.co/uKasdYEwnY

Many therapy studies call themselves, “single-blind”, however, this when the subject is blind, not when assessors are blind. “Single-blind” is misleading the reader that there is some control of bias when there is not. Us: https://t.co/sooQBqR2nb.

Douglas Berger Tokyo psychiatrist: Antidepressants show efficacy under double blind https://t.co/mgUktrrS97

Douglas Berger Tokyo psychiatrist: Blind placebo pills give 30% improvement in depression https://t.co/DopRqQA0E0

Load More...

Brain changes in Mindfulness Based therapy was unblinded with only 16 subjects: https://t.co/CC4HlhldEi. If you look at many brain sections you may find something by chance, you need to half your p value for each section looked at, not done here. Us: https://t.co/kbQF1wSzGN

Tokyo Counseling Service on ADHD https://t.co/LPwy8DzMbB @YouTubeさんから

Antidepressants show efficacy under double blind vs blind placebo because blinding filters out hope and expectation. Neither randomization nor blind assessment can make up for the loss of control from no-blind, no placebo conditions. Us: https://t.co/tReJReVhnP

Blind placebo pills give 30% improvement in depression. In depression drug trials, “non-inferiority” is very easily obtained as everyone responds to the placebo effect. Superiority studies have a higher statistical hurdle than non-inferiority studies. Us: https://t.co/CcbDgs5z45.

Medication vs psychotherapy isn't valid in a clinical trial because you can't double blind all the arms. Its uncontrolled clinical data, endpoints are subjective, and medications require double blinding or blind placebo: https://t.co/WLIjKdXqXL.

Load More...